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Genes in Patients with Se´zary Syndrome
Aparna Prasad1,2,3,4, Raquel Rabionet1,2,3,4, Blanca Espinet4,5, Luis Zapata1,2,3, Anna Puiggros4,5,
Carme Melero4,5, Anna Puig1,2,3,4, Yaris Sarria-Trujillo1,2,3,4, Stephan Ossowski1,2,
Maria P. Garcia-Muret6, Teresa Estrach7, Octavio Servitje8, Ingrid Lopez-Lerma9,
Fernando Gallardo4,10, Ramon M. Pujol4,10 and Xavier Estivill1,2,3,4,11Se´zary syndrome is a leukemic form of cutaneous T-cell lymphoma with an aggressive clinical course. The
genetic etiology of the disease is poorly understood, with chromosomal abnormalities and mutations in some
genes being involved in the disease. The goal of our study was to understand the genetic basis of the disease by
looking for driver gene mutations and fusion genes in 15 erythrodermic patients with circulating Se´zary cells, 14
of them fulfilling the diagnostic criteria of Se´zary syndrome. We have discovered genes that could be involved
in the pathogenesis of Se´zary syndrome. Some of the genes that are affected by somatic point mutations
include ITPR1, ITPR2, DSC1, RIPK2, IL6, and RAG2, with some of them mutated in more than one patient. We
observed several somatic copy number variations shared between patients, including deletions and duplica-
tions of large segments of chromosome 17. Genes with potential function in the T-cell receptor signaling
pathway and tumorigenesis were disrupted in Se´zary syndrome patients, for example, CBLB, RASA2, BCL7C,
RAMP3, TBRG4, and DAD1. Furthermore, we discovered several fusion events of interest involving RASA2,
NFKB2, BCR, FASN, ZEB1, TYK2, and SGMS1. Our work has implications for the development of potential
therapeutic approaches for this aggressive disease.
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Se´zary syndrome (SS) is considered the leukemic variant of
mycosis fungoides (MF), the most common type of cutaneous
T-cell lymphoma (CTCL). SS is classically manifested by the
triad of pruritic erythroderma, generalized lymphadenopathy,
and the presence of atypical large circulating mononuclear
cells with convoluted nuclei (Se´zary cells) (Olsen et al.,
2011). The prevalence of SS is approximately 0.3 cases per
100,000 people, and it accounts for less than 5% of all CTCLs.
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an open access artpatients and is more prevalent in men than women, with a
ratio of 2:1. It is an aggressive disease with a poor outcome.
(The 5-year overall survival rate is between 30 and 40%). SS
may develop de novo or in a patient with a previous diagnosis
of MF. The disease generally is much more aggressive, pro-
gresses faster, and is more resistant to treatment than classical
MF (Agar et al., 2010; Scarisbrick et al., 2015). The genetic
etiology of CTCL is largely unknown. Cytogenetic studies of
SS have identified abnormalities on chromosomes 1p, 2p, 6q,
9, 10q, 13q, 17p, and 21 (Brito-Babapulle et al., 1997; Espinet
et al., 2004; Johnson et al., 1985; Karenko et al., 1997; Limon
et al., 1995; Sole´ et al., 1994).
Next-generation sequencing approaches have revolution-
ized cancer genomics research with successful application to
the study of many hematological cancers, including chronic
lymphocytic leukemia (Puente et al., 2011; Quesada et al.,
2012), acute myeloid leukemia (Ding et al., 2012; Ley
et al., 2008; Mardis et al., 2009), diffuse large B-cell lym-
phoma (Ngo et al., 2011; Pasqualucci et al., 2011), and
Burkitt’s lymphoma (Schmitz et al., 2012). Recently, several
studies looking at the mutational landscape of CTCL and SS
identifying key genomic alterations have been reported (Choi
et al., 2015; da Silva Almeida et al., 2015; Kiel et al., 2015;
McGirt et al., 2015; Pe´rez et al., 2015; Ungewickell et al.,
2015; Vaque et al., 2014; Wang et al., 2015). Genes
involved in T-cell activation and apoptosis, NF-kB signaling,
chromatin remodeling, and DNA damage response have
been found to be altered (Choi et al., 2015). In addition,
signaling pathways including Jak/signal transducer and acti-
vator of transcription (STAT) signaling and cell-cycle check-
point have been shown to be involved in the pathogenesis of
CTCL (Pe´rez et al., 2015; Wang et al., 2015).s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Landscape of somatic point mutations identified in patients with
Se´zary syndrome. (a) Distribution of number of somatic point mutations per
sample. This includes somatic synonymous and nonsynonymous mutations
and those affecting splice sites. (b) Representation of transitions and
transversions per sample. A, adenine; C, cytosine; G, guanine; SNV, single
nucleotide variation; T, thymine.
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Driver Mutations in Se´zary SyndromeFusion genes play an important role in tumor development
because they might result in disruption of either tumor sup-
pressor genes or activation of proto-oncogenes. Targeting
small molecules to these fusion gene products could be
crucial in the treatment of cancer. A highly expressed gene
fusion between CTLA4 and CD28 was discovered in SS in
two independent studies (Sekulic et al., 2015; Ungewickell
et al., 2015). Here, we have applied whole-exome and
RNA sequencing approaches to 15 erythrodermic patients
with circulating Se´zary cells, 14 of them fulfilling the diag-
nostic criteria of SS patients, to study the genomic landscape
of SS. We have evaluated the somatic mutation spectrum in
these samples to identify putative driver mutations in genes
involved in the progression of the disease. In addition, we
have analyzed their transcriptome to search for fusion genes.
RESULTS AND DISCUSSION
Spectrum of somatic point mutations
We observed a median of 54 somatic point mutations (range,
4e88) in SS patients (Figure 1a and see Supplementary
Table S1 online). Two patients (SS06 and SS09) had a rela-
tively low number of somatic point mutations compared with
the other patients. One of these (patient SS06) turned out to
have a diagnosis of pre-SS. Of all the mutations, 68% of them
were C>T transitions (Figure 1b). A higher percentage of C>T
transition mutations has also been reported in previous
studies involving CTCL, and the possibility of the contribu-
tion of UV exposure to MF has been discussed (Choi et al.,
2015; McGirt et al., 2015).
We have identified four genes with recurrent somatic
mutations in this cohort of SS patients: TP53, ITPR1, DSC1,
and PKHD1L1 (Figure 2). Somatic mutations in TP53 were
found in three patients, including one stop-gain mutation.
Recurrent mutations in TP53 have been reported in patients
with CTCL (Choi et al., 2015), SS, and MF (Ungewickell
et al., 2015), but recurrent mutations in ITPR1, DSC1, and
PKHD1L1, to our knowledge, have not been previously re-
ported in studies of SS. We found damaging somatic muta-
tions in ITPR1 in two SS patients. A common variant in the
gene ITPR1 has been shown to be associated with suscepti-
bility to breast cancer (Michailidou et al., 2013). ITPR1 me-
diates calcium release from the endoplasmic reticulum, and
one of the predicted functional partners of ITPR1 is BCL2,
which suppresses apoptosis in different cell systems,
including lymphohematopoietic and neural cells (Snel et al.,
2000; STRING: protein-protein Interaction Networks, 2000).
The other gene in which we found highly damaging somatic
mutations in two patients was DSC1, which has been shown
to be associated with different cancer types, including colo-
rectal cancer and liver metastasis (Khan et al., 2006; Schu¨le
et al., 2014). Lastly, somatic mutations in two SS patients
were observed in PKHD1L1, including one missense and one
stop-gain mutation. PKHD1L1 is a homologue of the auto-
somal recessive polycystic kidney disease gene, and it en-
codes a receptor with inducible T-lymphocyte expression,
suggesting a role in cellular immunity (Hogan et al., 2003).
Somatic mutations in PKHD1L1 have been implicated in
gastric cancer in one study (Liu et al., 2014).
We identified several genes with singleton somatic muta-
tions in our patients, including PLCG1, STAT5B, GLI3,CARD11, NAV3, RIPK2, IL6, RAG2, and ITPR2 (see
Supplementary Figure S1 online). Some of these genes have
been previously shown to be associated with CTCL,
including PLCG1, STAT5B, GLI3, CARD11, and NAV3 (Choi
et al., 2015; da Silva Almeida et al., 2015; Karenko et al.,
2005; Kiel et al., 2015; Ungewickell et al., 2015; Vaque
et al., 2014; Wang et al., 2015). We found the same so-
matic mutation in PLCG1 (c.1034T>C, S345F) as reported
in the study of Vaque et al. (2014) and an N642H mutation in
the structurally conserved Src homology 2 (SH2) domain of
the STAT5B gene (Choi et al., 2015). The oncogenic potential
of the N642H mutation in STAT5B was shown earlier in
pediatric T-cell acute lymphoblastic leukemia (Bandapalli
et al., 2014; Kontro et al., 2014), in adult T-cell acute
lymphoblastic leukemia (Ma et al., 2015), and in large
granular lymphocytic leukemia (Rajala et al., 2013). We
observed a somatic missense mutation in CARD11 and a
stop-gain mutation (R792X) in GLI3 in our dataset. The cas-
pase recruitment domains (CARDs) of the CARD11 gene are
shown to interact with the CARD domain of BCL10, a protein
known to function as a positive regulator of cell apoptosis
and NF-kB activation (Bertin et al., 2001). CARD11 is
involved in the T-cell receptor signaling pathway, making it awww.jidonline.org 1491
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Figure 2. Recurrent somatic mutated genes in patients with Se´zary syndrome. The figure schematically represents the location of somatic mutation in the
protein structure of each gene. (aed) Structure of each gene and samples in which somatic mutations are detected are listed below each mutation. aa, amino
acid; Cad, cadherin prodomain like; G8, G8 domain; Ion_trans, ion transport protein; Ins, inositol 1,4,5-trisphosphate/ryanodine receptor; MIR, MIR domain;
RYD, RYDR_ITPR pfama, RIH domain; RIH, RyR and IP3R homology associated. The schematic representation of mutations are plotted using the tool
MutationMapper from the cBio cancer Genomics Portal (http://cbioportal.org) (Cerami et al., 2012; Gao et al., 2013).
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1492potential candidate gene for SS pathogenesis. We observed a
somatic point mutation (Chr12:78569178, G>A) in NAV3 in
one of our SS patients. A previous study identified NAV3 as a
putative tumor suppressor in CTCL, because 50e85% of
CTCL patients showed a deletion or translocation affecting
NAV3 (Karenko et al., 2005). However, a later study could
not confirm these observations (Marty et al., 2008). These
results were also not confirmed with our array comparative
genomic hybridization study on tumor stage MF (Salgado
et al., 2010). Somatic mutations in NAV3 have been re-
ported in other cancer types including breast, colorectal,
melanoma, and pancreatic carcinomas (Bleeker et al., 2009;
Wood et al., 2007). According to the Catalogue of Somatic
Mutations in Cancer (i.e., COSMIC), mouse insertional
mutagenesis experiments support NAV3 as a cancer driver
gene. To our knowledge, somatic point mutations in NAV3
have not been reported previously in CTCL studies. NAV3
may have a role in the regulation of IL2 production by T cells
and has also been predicted as a high-confidence cancer
driver using the IntOGen mutation analysis pipeline
(Gonzalez-Perez et al., 2013).
The other genes with singleton somatic point mutations
are IL6, RIPK2, RAG2, and ITPR2. IL6 and RIPK2 are key
components of regulation of CD4þ cells and activation/
differentiation of alpha-beta T cells involved in immune
response. We also observed a somatic missense mutation
affecting the plant homeodomain domain of RAG2 in one SS
patient. The plant homeodomain domain is found at the
C-terminus of the recombination activating gene (RAG) 2
protein, which modulates its recombination activity (Elkin
et al., 2005). This protein was shown to be involved in theJournal of Investigative Dermatology (2016), Volume 136process of T-cell differentiation in the thymus, and Choi et al.
(2015) reported enrichment of RAG heptamers in CTCL
breakpoints. It is important to note that somatic mutations
in some genes, including NAV3 (Chr12:78569178, G>A),
IL6 (Chr7:22767146, G>A), and ITPR2 (Chr12:26553068,
G>A), were detected only using the Agilent SureSelect
Target Enrichment Exome (Agilent Technologies, Santa Clara,
California, USA) but were missed from the experiments using
the Nextera Capture Exome (Illumina, San Diego, California,
USA). This was probably not because of different probe
coverage between the two capture kits but because the
Mutect application was unable to detect these mutations
from the Nextera experiments. We used Sanger sequencing
to validate these mutations by ruling out false-positive
results.
We do not see a similar rate of recurrence for some of the
mutations as has been observed in earlier studies, for
example, for PLCG1 and CARD11. This is mainly because of
the small sample size of our dataset compared with those of
other studies (Kiel et al., 2015; Wang et al., 2015). PLCG1
was first found to be mutated in 9% of the patients with SS
(Vaque et al., 2014). In one of the largest studies on SS, the
frequency of PLCG1 mutations was 14% (5 of 37 patients) in
the original cohort, and it increased to 21% (14 of 68 pa-
tients) in the extension cohort (Wang et al., 2015). Some
previous studies have investigated CTCL, which includes
patients with both MF and SS. Therefore, both the diagnostic
heterogeneity among studies and the clinical heterogeneity of
SS per se could contribute to the fact that only some genetic
alterations are common between the different studies
performed.
Figure 3. Landscape of somatic copy number variations and fusion events detected in patients with Se´zary syndrome. A Circos plot showing a representation
of somatic copy number variations and fusion transcripts for 12 Se´zary syndrome samples for which DNA sequence data were available. The colored tracks on
the rim of the circle represent duplications and deletions. The light green-colored track represents duplications, and the pink colored track represents deletions.
The colored lines in the innermost circle show fusion transcripts. This figure is generated using Circos software package (Krzywinski et al., 2009).
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We found 61 somatic duplications across 10 patients, with an
average of six duplications per patient (see Supplementary
Table S2 online and Figure 3). Somatic duplications on
chromosome bands 8p23.3eq24.3 (103e146 megabases
[Mb]) and 17p11.2eq23.2 (18e21 Mb) were observed in
three patients. Among the large-sized duplications (>5 Mb),
we observed a somatic duplication of entire chromosome
4, entire chromosome 18, a 26-Mb duplication on
10p15.3ep12.2, and a 19-Mb and a 17-Mb duplication on
chromosome 1. Several of the focal somatic duplications(2p15, 3p26.3, 5q23.1, 6p12.3, 7p15.2, 7p12.3ep13, 7q34,
10p12.1, 10q21.3, 12q24.31, 13q21.33, 16p11.2, 16p13.3,
19p13.2, and 19q13.32) encompassed genes that play a role
in tumorigenesis or have been found to be involved in several
different human cancer types.
We found a 6-kilobase (kb) duplication involving several
exons of ANKRD26 on 10p12.1, encoding a protein con-
taining N-terminal ankyrin repeats, which function in
protein-protein interactions. Mutations in this protein are
associated with autosomal-dominant thrombocytopenia and
myeloid malignancies (Noris et al., 2013). In addition, thewww.jidonline.org 1493
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149432-kb duplication on chromosome band 16p11.2 involves
part of the tumor suppressor BCL7C gene (Uehara et al.,
2015). Another duplication of interest is 29-kb duplication
on chromosome band 6p21.1 that encompasses some exons
of CRIP3, which is involved in the process of T-cell prolifer-
ation. In addition, we observed a 463-kb duplication of
chromosome bands 7p12.3e13, encompassing three genes,
including TBRG4 and RAMP3. TBRG4 encodes transforming
growth factor-beta regulator 4, and RAMP3 encodes a protein
involved in the G-protein coupled receptor signaling
pathway.
Landscape of somatic deletions
A total of 60 somatic deletions were observed across 10
SS samples, with a median of 5 deletions per sample (see
Supplementary Table S3 online and Figure 3). Several large
deletions (>5 Mb) were shared by patients: a 55e110-Mb
deletion on 10p11.1eq26.3 in two patients, a 17-Mb dele-
tion on 11q23.3eq25 in two patients, a 15e25-Mb deletion
on 17p12ep13.3 in six patients (encompassing several genes
including TP53), and a 9-Mb deletion on 19p13.2ep13.3 in
two patients.
We observed a somatic deletion of approximately 600 kb
on 14q11.2 in patients SS02 and SS07 affecting the DAD1
gene. The loss of DAD1 protein has been shown to trigger
apoptosis (Yulug et al., 1995), and DAD1 protein over-
expression is found to be associated with small bowel
carcinoid tumors (Kulke et al., 2008). Another interesting
example is a 100-kb deletion on 3q23 encompassing several
exons of RASA2 in patient SS01. RASA2 encodes a proto-
oncogene that plays an important role in the mitogen-
activated protein kinase signaling pathway that is involved
in various cellular functions, including cell proliferation,
differentiation, and migration. In the same patient (SS01), we
observed another interesting deletion (210 kb) on 3q13.11
encompassing the CBLB gene (da Silva Almeida et al., 2015).
CBLB encodes a proto-oncogene involved in T-cell activa-
tion, negative regulation of the T-cell receptor signaling
pathway, and negative regulation of alpha-beta T-cell prolif-
eration (Elly et al., 1999). In activated T cells, CBLB inhibits
PLCG1 activation and calcium mobilization upon restim-
ulation (Yasuda et al., 2002). The entire chromosome 3 was
alternated by duplications and deletions in patient SS01 and
was possibly affected by chromothripsis-like rearrangements.
In our patients, chromosome 17 was largely affected by
genomic changes, including somatic point mutations and
copy number variations. Of special interest is the gene TP53,
which was affected in 58% of patients (7 of 12), either by
somatic point mutations or by somatic deletion with a so-
matic copy number variation (CNV)/somatic single nucleo-
tide variant (SNV) ratio of 2:1. Although a previous study
reported 92.5% of patients with CTCLs (n ¼ 40) with a so-
matic CNV:SNV ratio of 5.1:1 (Choi et al., 2015), the differ-
ence is likely due to the low number of samples (n ¼ 12) in
our study on which we have exome sequencing data avail-
able. Somatic point mutations in the TP53 gene were seen in
three patients—SS03, SS10, and SS12—whereas large de-
letions on 17p involving the TP53 gene were detected in six
patients, including SS01, SS02, SS03, SS08, SS10, and SS11.
We identified two patients with a double-knockout TP53Journal of Investigative Dermatology (2016), Volume 136clone. Patient SS03 harbors a 25-Mb deletion on 17p
encompassing TP53 and present in almost all the cells of the
patient. This patient also has a subclonal mutation in TP53. It
is likely that, because of the strong effect of complete loss of
functional TP53, this clone would be positively selected and,
over the course of time, could dominate the tumor popula-
tion. Patient SS10 has both a stop-gain mutation in TP53 and
a 15-Mb deletion on 17p encompassing TP53 and is clonal—
that is, affecting all the cells—resulting in no functional copy
of the TP53 gene in this patient. These two patients were
diagnosed at a relatively early age compared with the rest of
the patients, but statistics are insufficient to claim that this is
because of the presence of a homozygous loss of TP53.
Fusion events
A total of 86 potential fusion events were observed across 10
SS samples (see Supplementary Table S4 online). Fusion
RNAs including TYK2-UPF1, COL25A1-NFKB2, FASN-
SGMS1, SGMS1-ZEB1, SPATA21-RASA2, PITRM1-HK1, and
BCR-NDUFAF6 were successfully validated. Complex chro-
mosomal rearrangements were observed in two of our pa-
tients (SS04 and SS13), as was evident with the fusion events
identified in these patients (see Supplementary Figure S2
online). Patient SS04 had fusion events FASN-SGMS1 and
SGMS1-ZEB1. The protein of fatty acid synthase (FASN), in
some cancer cell lines, gets fused with estrogen receptor-a, in
which the N-terminus of fatty acid synthase is fused in-frame
with the C-terminus of estrogen receptor-a (Entrez gene,
2008). FASN is involved in several cancer types, including
hepatocellular carcinoma, colorectal cancer, and prostate
cancer (Hao et al., 2014; Madigan et al., 2014; Zaytseva
et al., 2014). The other partner of the fusion gene FASN-
SGMS1 is sphingomyelin synthase 1 (SGMS1), the activity
of which is regulated by the breakpoint cluster region-ABL
proto-oncogene, non-receptor tyrosine kinase oncogene. The
partner ZEB1 of the SGMS1-ZEB1 fusion gene encodes a zinc
finger transcription factor and acts as a transcriptional
repressor of IL2. The ZEB1 gene is involved in the process of
regulation of T-cell differentiation in the thymus and has been
strongly implicated in the pathogenesis of CTCL and SS (Choi
et al., 2015; Kiel et al., 2015; McGirt et al., 2015; Wang
et al., 2015). Patient SS13 had both TYK2-UPF1 and
COL25A1- NFKB2 fusion events. The TYK2 gene was shown
to be essential for the differentiation and function of different
immune cells, including natural killer cells, B cells, and
T-helper cells (Liang et al., 2014). The gene NFKB2 is a
pleiotropic transcription factor that is involved in several
pathways including NF-kB signaling, which regulates the
transcription of many genes involved in cancer initiation and
progression. NFKB2 was shown to be disrupted in earlier
CTCL studies (Choi et al., 2015; Ungewickell et al., 2015),
and the effectiveness of using NF-kB inhibitors such as bor-
tezomib has been discussed in a phase II trial (Zinzani et al.,
2007). We observed the fusion gene SPATA21-RASA2 in
patient SS01, in whom we also observed the 100-kb somatic
deletion on 3q23 encompassing almost all exons of RASA2,
indicating the mechanism behind formation of this fusion
gene. The PITRM1-HK1 fusion event was found in patient
SS05. The elevated level of hexokinase 1 has been shown to
promote tumor cells to avoid apoptosis, thereby allowing cell
Table 1. Summary of key genomic changes detected across all 15 patients1
SS01 SS02 SS03 SS04 SS05 SS06 SS07 SS08 SS09 SS10 SS11 SS12 SS13 SS14 SS15
TP53/17p e e X/e e X*/e e X
ITPR1 X X
DSC1 X X
PKHD1L1 X X*
PLCG1 X
STAT5B X
GLI3 X*
CARD11 X
NAV3 X
IL6 X
RIPK2 X
RAG2 X
ITPR2 X
RASA2 e
CBLB e
ALDH1A1 X
1p21.2e31.3 e
1q25.3e31.3 þ
1p36.13e36.33 þ
2q37.2e37.3 e
2q24.1e24.2 e
Entire chromosome 4 þ
6p21.1 (CRIP3) þ
6q22.31 e
7p12.3-13 (TBRG4, RAMP3) þ
8p11.1eq24.3 þ þ þ
8p11.21e23.3 e
9p11.1eq22.32 e
10p12.1e15.3 þ
10p11.1eq26.3 e e
10p12.1 (ANKRD26) þ
11q23.3e25 e e
14q11.2 (DAD1) e e
16p11.2 (BCL7C) þ
16q21 þ
17p11.1eq25.3 þ þ þ
Entire chromosome 18 þ
19p13.11 (PDE4C) e
19p13.2e13.3 e e
SPATA21-RASA2 ǂ
FASN-SGMS1 ǂ
SGMS1-ZEB1 ǂ
PITRM1-HK1 ǂ
ATM (germline splice mutation) F
TYK2-UPF1 ǂ
COL25A1-NFKB2 ǂ
chr9:4434675-4434705:MLLT3 ǂ
BCR-NDUFAF6 ǂ
X denotes somatic single nucleotide variant; X* denotes somatic stop-gain single nucleotide variant; þ denotes somatic duplication; e denotes somatic
deletion; ǂ denotes fusion event; F denotes germline splice-site mutation in the ATM.
1The genes and the genetic alterations that, to the best of our knowledge, have not been reported in previous studies of Se´zary syndrome are highlighted in
bold. It is important to mention that translocations/deletions in NAV3 have been reported in an earlier study (Karenko et al., 2005). However, somatic
mutations have not been reported in NAV3 in cutaneous T-cell lymphoma. In addition, somatic mutations in ATM have been previously reported. We have
not seen studies reporting germline mutations in ATM in Se´zary syndrome earlier.
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patient SS15, we observed a fusion gene involving BCR-
NDUFAF6. A BCR-ABL fusion transcript involving exon 8
and exon 4, respectively, has been reported in a SS patient(Callet-Bauchu et al., 2007). Table 1 summarizes the key
somatic genomic changes across 15 patients.
In patient SS09, we did not observe any somatic point
mutation or copy number variation that could be involved inwww.jidonline.org 1495
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1496the pathogenesis of disease in this patient. Although the focus
of this study was primarily on somatic mutations, we found a
germline splice-site mutation (NM_000051:exon16:c.2377-
2A>G) in the ATM gene in this patient. The variant has an
allele fraction of 0.567, as expected for a heterozygous
germline mutation present in all cells of the patient in a
diploid locus. This splice-site mutation is affecting the FAT
(FRAP, ATM, TRAPP) domain of ATM (ATM serine/threonine
kinase). Although the function of this domain is not clear, it
has been suggested that the FAT domain interacts with the
kinase domain to stabilize the carboxy-terminal end of the
protein (Bakkenist and Kastan, 2003). ATM is an important
mediator of the DNA damage response pathway. However, in
the absence of supporting biological data, we cannot
conclude that this particular germline mutation is involved in
disease susceptibility in this patient.
Our study presents a complex genomic landscape of SS
with several somatic point mutations, copy number variations,
and fusion events that could contribute to the pathogenesis of
SS. Based on the evidence from our studies and previous
studies, it is likely that genes TP53, ITPR1, PLCG1, CARD11,
STAT5B, RASA2, CBLB, DAD1, TYK2, FASN, SGMS1,
NFKB2, ZEB1, HK1, and BCR could be involved in the path-
ogenesis of the disease. A number of somatic deletions and
duplications identified in this study were shared among
patients, indicating that chromosomal instability is a feature
of this type of lymphoma. Finally, the fusion genes identified
in this study could be targeted for therapeutic implications.
MATERIALS AND METHODS
Sample collection
Fifteen erythrodermic patients presenting with circulation of atypical
cerebriform lymphoid cells (Se´zary cells) were selected for study.
Fourteen patients fulfilled the diagnostic criteria for SS with B2 level
of blood involvement proposed by the International Society for
Cutaneous Lymphomas (i.e., ISCL) and the European Organization
for Research and Treatment of Cancer (i.e., EORTC) (Olsen et al.,
2011), and one patient with the de novo erythroderma had less
than 1,000 circulating Se´zary cells/mm3 (B1 level of blood
involvement) (see Supplementary Table S5 online). B2 level of blood
involvement is defined as clonal rearrangement of the T-cell receptor
(TCR) in the blood and either 1.0 K/mL or more Se´zary cells or one
of the 2 criteria outlined by the ISCL, that is, (1) increased CD4þ
or CD3þ cells with CD4/CD8 of 10 or more or (2) increase
in CD4þcells with an abnormal phenotype ( 40% CD4þ/CD7 or
 30% CD4þ/CD26) (Vonderheid et al., 2002). Samples came from
five different sites in Barcelona: Hospital del Mar, Hospital del Sant
Pau, Hospital Clinic, Hospital de Bellvitge, and Hospital Vall
d’Hebron. Biological samples from Hospital del Mar were obtained
from Parc de Salut MAR Biobank (MARBiobanc). The participation of
human subjects in this study was approved by the institutional
review board of each hospital, and written informed consent
was obtained following Helsinki protocols. Peripheral blood
samples were collected for each patient, and CD4þ T lymphocytes
were isolated by using magnetic beads (Miltenyi Biotec, Auburn,
California, USA). Granulocytes were isolated by dextran sedimen-
tation to obtain matched normal cells. DNA was extracted using the
Gentra Puregene Blood Kit (Qiagen, Hilden, Germany). RNA was
extracted from matched normal and tumor materials for a total of
10 SS samples using the miRNeasy kit (Qiagen). RNA sequencingJournal of Investigative Dermatology (2016), Volume 136was performed on these samples. However exome as well as RNA
sequencing data were obtained for only seven of them, as detailed in
Supplementary Table S6 online.
Whole-exome sequencing
DNA libraries for 12 matched tumor (CD4þ) and normal (gran-
ulocyte) cells from SS patients were prepared using the Illumina
Nextera DNA Sample Prep kit (Illumina, San Diego, California,
USA). The exomes were captured using Nextera rapid capture
exome (37 Mb) and sequenced on the Illumina HiSeq 2000 platform
as a 100-base pair paired-end run. In addition, genomic DNA from
six samples was also captured using the Agilent SureSelect Human
All Exon v4 þUTR kit (71 Mb) (Agilent Technologies, Santa Clara,
California, USA). The library enriched for target regions was
sequenced on the Illumina HiSeq 2000 platform as a 100-base pair
paired-end run. The average depth of coverage for the samples
captured using the Nextera capture kit was 37 (range ¼ 25e48),
whereas for the samples captured using the Agilent SureSelect
capture kit it was 31 (range ¼ 23e49) of coverage (see
Supplementary Table S7 online).
Alignment and SNV calling
The reads generated from the sequencer were aligned to the human
genome reference sequence (hg19) using Burrows-Wheeler align-
ment (BWA-maximal exact match algorithm) (Li and Durbin, 2009).
Any duplicate reads were flagged using the MarkDuplicates algo-
rithm from Picard (http://broadinstitute.github.io/picard/). Base
quality recalibrations were performed using The Genome Analysis
Toolkit haplotype caller (DePristo et al., 2011). Somatic SNVs were
detected using MuTect (Cibulskis et al., 2013) and were filtered
following the standard recommendation to obtain a set of confident
calls. The somatic SNVs obtained using MuTect were further anno-
tated, providing information about the impact of the mutation, the
damage potential, and the allele frequency of the somatic SNV in the
1000 Genome (1000 Genomes Project Consortium, 2010) and
the Exome Variant Server database (National Heart, Lung, and Blood
Institute Exome Sequencing Project, found at http://evs.gs.
washington.edu/EVS/). A subset of candidate somatic mutations
was validated by Sanger sequencing in CD4þ and granulocyte DNA
as control. We analyzed the exome sequencing data for somatic
point mutations from both Agilent and Nextera capture kits. For
simplification, all the statistics presented in this study are from the
Nextera kit, because it was used for all the DNA samples.
Identification of somatic CNVs
Somatic CNVs were identified using an in-house algorithm ClinCNV
(manuscript in preparation). ClinCNV computes coverage within
samples and across a set of samples and infers CNVs by referring each
sample to the computed average and to its matched pair (if available).
Further support for CNV is obtained by calculating changes in allele
frequency in tumor samples versus matched normal control samples.
To define putative deletions and duplications, we established the
cutoffs for deletions and duplications at a tumor-to-normal ratio of
less than 0.7 and greater than 1.3, respectively, with greater than 77%
significant probes in the region. This threshold was relaxed for only
one deletion on chromosome 17 in three patients (SS03, SS10, SS11)
because the deletion was present in high confidence in three of the
other patients, had been reported earlier in literature (Caprini et al.,
2009; Vermeer et al., 2008), and was likely to be a true positive.
ClinCNV computes the cancer cell fraction for each CNV using an
analytical formula published previously (Bassaganyas et al., 2013).
A Prasad et al.
Driver Mutations in Se´zary SyndromeRNA sequencing and fusion transcript discovery
Stranded messenger RNA libraries for 10 tumor (CD4þ) samples
were generated by polyA selection using the NEBNext Ultra
Directional RNA Library Prep Kit for Illumina library preparation kit
(New England Biolabs Inc., Ipswich, MA), starting from 700 ng of
total RNA. Libraries were sequenced on three lanes of the Illumina
Hiseq2500 sequencing platform as a 125-base pair paired-end
run. Quality check of the data was performed using FastQC (Bab-
raham Institute, Babraham, Cambridge, United Kingdom; available
at http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The
sequencing data for messenger RNA was aligned to the reference
genome using STAR (Spliced Transcripts Alignment to Reference),
applying parameters optimized for the detection of chimeric reads
(Dobin et al., 2013). The resulting potential fusion transcripts were
further evaluated both manually and using the R Bioconductor
package Chimera (version 1.12.0) (Beccuti et al., 2014). A minimum
of 10 supporting (spanning) reads was used as a threshold for fusion
transcripts, and the sequence around donor and acceptor sites of
potential chimeric reads was manually evaluated to discard potential
false positives. We visually inspected Integrated Genome Viewer
(Robinson et al., 2011) and RNA expression data and selected some
fusion events for validation by real-time PCR.
Accession codes
The exome and RNA sequencing data have been deposited at the
European Genome-Phenome Archive (available at http://www.ebi.
ac.uk/ega/), which is hosted at the European Bioinformatics insti-
tute under accession number EGAS00001001706.
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